

Index

Key: t = table; f = figure; ph = photo

- Abandonment
 - law of conversion and trespass to chattel, 82
- Access to human biological materials
 - interested parties, 49-64
- Accession law
 - source of rights relating to human biological materials, 83-84, 87
- Adrenalin crystals
 - patentable, 71
- Aging, human
 - study with primary cell cultures, 33
- Agricultural doctrine
 - applicability to cases involving human biological materials, 83-84, 85
- Alabama commercial code
 - implied warranties in sales of human blood and tissues, 77
 - tax on blood sales, 78
- American Law Institute
 - on wrongful acts toward cadavers, 73
- Andrews, Lori B.
 - on property rights to body parts, 127
- Angiogenin
 - commercialization, 60
 - research and development, 60, 61f
- Antibodies
 - composition and structure, 37
 - monoclonal, 5, 37-38, 39f, 44, 62
 - polyclonal, 37
 - production and function, 5, 35, 37, 38
- Autonomy
 - libertarian view of justice, 135-136
- Autopsies
 - Law and religion, 72-75, 87, 139
- Availability of human biological materials
 - effect of commercialization, 116, 124-125, 135
 - equity, 12
- B lymphocytes
 - hybridomas, 38
 - immune response, 37
- Battery law
 - applicability to consent issues, 93-94, 110
- Beneficence
 - ethics of buying and selling bodies and their parts, 134-135
- Bernard, Claude
 - on research on biological materials, 29
- Biopharmaceuticals
 - commercial potential, 50-51
 - development and testing, 31, 58-59, 59t, 60, 61f, 154
 - estimated U.S. marketing dates, 58t
 - licensing, 61
- Biotechnology
 - definition, 24
 - history and development, iii, 23
 - industry, 8, 52, 56-63, 119
 - issues, iii
- Biotherapeutics, Inc.
 - fee-for-service research, 62
- Blood and blood products
 - donation, 52, 117-118, 141, 212
 - lymphokine content, 39-40
 - marketing, 12, 24, 76-78, 87, 117-118
 - ownership, 26
- Bodies and their parts
 - moral status, 130-134, 136, 137-144
- Bone marrow, human
 - collection and payment by the National Institutes of Health, 52
- Brenner v. Manson**
 - Supreme Court decision on patentability, 71
- Cadavers
 - dissection, 140f
 - emotional distress claims, 72-75
 - "Judeo-Christian tradition," 138-139, 141, 142
 - law, 72-75, 87
 - sources of human tissue, 7, 51
 - wrongful acts toward, 72-73
- California law
 - accession, 85-86
 - disposal of human biological materials, 80
- Cancer cells
 - fusion with T lymphocytes to produce hybridomas, 40
 - National Cancer Institute network, 53
- Cancer treatment
 - fee-for-service research, 62
- Carcinogenesis
 - use of cell fusion in research, 35
- Cartesian philosophy
 - moral status of bodies and their parts, 137-138, 142
- Case histories
 - angiogenin development, 60, 61f
 - Chakrabarty-Patent and Trademark Office organism patentability case, 49
 - coerced tissue donation, 77
 - Hagiwara case, 4, 26
 - hypothetical case concerning effect of commercialization on doctor-patient relationship, 14
 - hypothetical case concerning proper transfer and use of human biological materials, 129
 - ownership of human cells, 24-26
 - Stanford University cell line ownership case, 25
 - University of California, Los Angeles—Hoffman-LaRoche cell line ownership case, 25-26
 - University of California, Los Angeles—Moore ownership case, 26
- Catholicism
 - moral status of bodies and their parts, 141-142
- CCPA. See Court of Customs and Patent Appeals, U.S.
- Cell culture
 - commercialization, 3, 4, 16-17, 116
 - development and technology, 5, 8, 25f, 31-35, 36f, 40, 44, 55-56

- ownership, 3, 4, 17, 25
- patentability, 49-50
- repositories, 52-53
- trade secrets, 78
- transfers, 12, 52
- use, 35, 116-117
- Cell fusion
 - development and use, iii, 35, 38
- Cells, human
 - applicability of cadaver law, 73
 - commercial interest, 7, 24, 49-51, 54, 56-62
 - emotional distress claims, 73-75
 - genetic content and engineering, 6, 41-42
 - ownership, 24-27, 69-87
 - repositories, 52-53
 - storage, 33
 - trade secrets, 79, 87
 - uses, 7, 52, 54-55
- Cells, mammalian
 - compared with microbial cells, 31t
- Chakrabarty-Patent and Trademark Office case
 - patentability of organisms, 49, 50, 71
- Christianity
 - moral status of bodies and their parts, 138-139, 141-143
- Cloned genes, human
 - repositories, 52-53
 - uses, 34, 40, 44
- Clonetics Corp.
 - marketing of normal cloned human skin cells, 24
- Commerce in human biological materials
 - development of biotechnology products, 8, 50-51, 55-56, 60, 113, 119-121
 - effects on costs, 12-13, 116-117, 135
 - emotional distress claims, 74
 - equity of distribution, 116, 124-125
 - ethical considerations, 13-15, 127, 129-144
 - hypothetical case study, 14
 - informed consent, 17-19, 96
 - interest in research and inventions, 49-51, 56-62
 - legal considerations, 9, 50-51, 70, 72, 76-78, 83, 87
 - market system, 12, 119-121, 123-125, 134
 - physician/researcher and patient/subject relationship, 97
 - principle of beneficence, 134-135
 - principles of justice, 135
 - role of Federal Government, 15-19
 - safety and quality, 117-118
- Commissioners on Uniform State Laws
 - Uniform Anatomical Gift Act, 75
- Common law
 - physician's fiduciary duty, 82-83
 - property rights in corpses, 72
 - relevance to use of human tissues and cells, 9, 69, 86-87
 - res nullius, 82
 - rights of sources of human biological materials, 80, 93-94, 102, 110-111
- Compensation. See Payments
- Confidentiality
 - agreements, 78-79
 - Federal consent and disclosure regulations, 95, 100, 109-110
- Congress
 - effect of actions on **sources of human tissue**, 51
 - establishment of President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 99
 - House Committee on Science and Technology, 50, 52
 - National Organ Transplant Act, 75-76
 - patent policy, 50, 70
 - policy on use of human biological materials, 15-19
- Connecticut supreme court
 - on disclosure, 99-100
- Consent of source of human biological materials
 - ethical considerations, 131, 134, 135-136, 142
 - legal considerations, 73, 74-75, 93-94
 - market system for human biological materials, 120
 - physicians' obligations and patients' rights, 14, 99
 - policy considerations, 10-11
 - requirements, 17-19, 93-111, 113, 129, 152-153
 - Scholendorff v. Society of New York Hospital**, 91
- Contract law
 - relevance to human biological materials, 9, 17
- Conversion law
 - relevance to use of human biological materials, 79-83, 84-86, 87
- Copyright law
 - source of rights relating to human biological materials, 78, 87
- Corruption
 - possibility in distribution of human biological materials, 116, 117
- Court of Customs and Patent Appeals, U.S.
 - Chakrabarty-Patent and Trademark Office organism patentability case, 49
 - In re Bergey decision**, 49-50
- Deoxyribonucleic acid. See DNA
- Department of Commerce, U.S.
 - revised regulations, 50n
- Department of Health and Human Services, U.S.
 - regulation of research, 10, 11, 17-18, 94-95, 96, 97, 106, 107, 147-154
- Descartes, Rene
 - development of view of mind-body duality, 137
- Diamond v. Chakrabarty**
 - Supreme Court organism patentability decision, 49, 50, 71
- Disclosure to source of human biological materials requirements, 10-11, 102, 104-106, 110-111
- Scholendorff v. Society of New York Hospital**, 91
- DNA. See **also** Recombinant DNA
 - composition and function, 41-42
 - copyrightability, 78
- Dobson, Matthew
 - experiment with human biological materials, 23

- Dolnick, Edward
on commercial potential of human cells, 113
- Economic considerations
biotechnology, 63
use of human biological materials, 11-13, 113, 115-125
- Egalitarian view of justice
ethics of buying and selling bodies and their parts, 136
- Emotional distress
caused by acquisition and use of human biological materials, 72-75
- Employers' rights
"hired to invent" doctrine, 70-71
- Engelhardt, H. Tristram, Jr.
principle of respect for persons, 133-134
- Equity
effects of commerce in human biological materials, 12, 13, 115-116, 124-125, 135-136
- Ethical considerations
use of human biological materials, 13-15, 127, 129-144
- Families' rights
cadavers, 72-75, 131
- Federal Government
interest in human biological materials, 7, 15-19, 50
support for National Disease Research Interchange, 123
- Federal law and regulations
blood and semen sales, 76
blood plasma as property, 78
conversion and trespass to chattel, 79
copyright, 78
human research, 10-11, 17-18, 94-95, 96, 97, 100, 102, 104-110, 147-154
ownership rights, 25
patents, 49, 50, 70-72, 87
personal rights, 70, 86
testing of biotechnology products, 61, 154
use of human tissues and cells in biotechnology, 17-18
- Fee-for-service research
interested parties, 62
patients' costs, 62
- Financial gain from human biological materials
disclosure of prospect to source of human biological materials, 10-11, 102, 104-106, 110-111
effect on voluntariness of consent, 96, 97
ethical distribution, 130
Federal Government's rights, 17
interested parties, 49-63
sources' rights, 16-17
- Fletcher, Joseph
on moral status of bodies and their parts, 132, 142
- Food and Drug Administration, U.S.
regulations of biological materials and human research, 10, 54, 60-61, 94, 95
- For-profit institutions
interaction with nonprofit institutions, 123-124
regulation, 122
- Genentech
development and ownership of KG-1 cell line, 25
- General Electric
organism patentability case, 49
- Genes
clones, 6, 40, 41-44, 45, 52
composition and function, 41-42
excision with restriction endonucleases, 42-43
expression, 42f
probes, 16-17, 43-44
quantity in human cells, 41-42
use of monoclonal antibodies in research, 38
- Genetic engineering. See Recombinant DNA
- Government
interference in commercialization of human biological materials, 133-134, 135-136, 143
relationship with nonprofit institutions, 122-123
- Growth hormone, human
production and use, 45
- Hagiwara hybridoma
development and ownership dispute, 4, 26
- Harvard University Medical School
angiogenin research and development, 60
- "Hired to invent" doctrine
patent law, 70-71
- Hoffman-LaRoche
development and ownership of KG-1 cell line, 25-26
- House Committee on Science and Technology
survey of research use of human tissues and cells, 52
- House Committee on Science and Technology Investigations and Oversight Subcommittee 1985 survey on patent applications, 50
- HT-29 human tumor cell line
angiogenin development, 60
- Human rights
egalitarian view of justice, 136
- Hybridomas
commercial product, 3
fee-for-service research, 62
ownership, 4, 26
technology, 5, 6, 35, 37-40, 44, 52
- "Imago dei" doctrine
moral status of bodies and their parts, 138, 139
- Immunity
higher animals, 35, 37
hybridoma technology, 35, 37-40
- In re Bergey***
organism patentability, 49-50
- Industry
acquisition of human biological materials, 52
effects of 1980 patent law changes, 50-51
exploitation of biomedical research, 50
interest in human tissues and cells, 8, 56-62
payments to researchers and physicians, 61-62, 119
product development, 59t, 61
profits from government-funded research, 17
relationships with universities, 7, 54, 61-62, 119

- transfers of human biological materials, 52**
- use of rodent monoclonal antibodies, 38**
- Informed consent. See Consent
- Injuries
 - law of conversion and trespass to chattel, 81-82
 - rights relating to human biological materials, 69-70
- “Innovation lag” in commercial exploitation of research
 - congressional concern, 50
- Institutional Review Boards
 - approval of research, 17-18, 95, 96, 100, 102, 105, 109-110, 149-151
- Insulin, human
 - production and use, 45
- Insurance
 - ownership and use of human biological materials, 4, 27
- Interagency Human Subjects Coordinating Committee
 - regulation of human research, 94
- Interferon
 - occurrence in human blood, 39-40
 - production and therapeutic use, 6, 25-26, 40, 44, 45
- Interleukin-2
 - therapeutic use, 40, 62
- Inventions
 - biological, 7, 24, 49-51, 63
 - inventors’ rights, 16, 70-72, 87
 - legal definition, 71-72
- Judaism
 - moral status of bodies and their parts, 138-139, 141
- “Judeo-Christian tradition”
 - moral status of bodies and their parts, 138-139
- Justice
 - ethics of buying and selling bodies and their parts, 13-14, 15, 135-136
- Kant, Immanuel
 - on moral status of bodies and their parts, 142
- Kass, Leon R.
 - on control of biomedical research, 47
 - principle of respect for persons, 132-133
- KG-1 cell line
 - development and ownership, 25-26
- Kidney procurement system
 - corruption, 116
- Kohler, Georges
 - discovery of hybridoma production technique, 38
- Legal considerations
 - biotechnology, 63
 - injuries to persons versus injuries to property, 69-70
 - market for human biological materials, 124
 - ownership of human biological materials, 9, 24-27, 52
 - possible sources of rights relating to human biological materials, 70-84, 87
 - remedies, 84-86
 - use of human biological materials, 9, 69-87
- Liability
 - blood and semen sales, 76-77
 - insurance, 27
 - specimen users, 4
 - tissue conversion cases, 86
- trade secrets law, 78**
- Libertarian view of justice
 - commercialization of human biological materials, 135
- “Liver Tissue Procurement and Distribution System”
 - establishment and purpose, 53
- Lymphocytes
 - immune response, 37
- Lymphokines
 - fee-for-service research, 62
 - function in immune response, 38-39
 - technology, 5, 37, 38-40
 - therapeutic use, 40
- Macrophages
 - function in immune response, 38-39
- McCormick, Richard
 - on organ donations, 141
- Medical Research Council’s Laboratory of Molecular Biology
 - discovery of hybridoma production technique, 38
- Medical treatment
 - consent and disclosure requirements, 93-100, 102, 104, 110-111
- Mendel
 - principles of genetics, 41
- Micro-organisms
 - as trade secrets, 78
 - ownership, 133
- Milstein, Cesar
 - discovery of hybridoma production technique, 38
- “Mo” cell line
 - development and ownership, 26
- Monoclonal antibodies
 - technology and use, 5, 37-38, 39f, 44, 62
- Monsanto Co.
 - angiogenin research and development, 60
- Moore, John
 - congressional testimony on patients’ rights, 21
 - development and ownership of “Mo” cell line, 26
- Morality. See Ethical considerations
- Murray, Thomas H.
 - congressional testimony on sharing of profits from human biological materials with sources, 67
 - on sale of body parts, 127
- National Cancer Institute
 - development and ownership of KG-1 cell line, 25
 - establishment of cancer tissue network, 53
 - experimental cancer treatments, 62
- National Disease Research Interchange
 - establishment and operations, 53, 123
- National Institutes of Health
 - collection of blood and bone marrow for research, 52
 - establishment of National Disease Research Interchange, 123
 - ownership dispute over WI-38 cell line, 25
 - patent policy, 50
 - regulation of human research, 94

- support of human-related research, 52
- support of repositories of human biological materials, 53
- National Organ Transplant Act
 - model for statute prohibiting buying and selling human tissues and cells, 16
 - regulation of human organ donation and sales, 3, 75-76
- Negligence law
 - applicability to consent issues, 94, 110
- Nonmarket system
 - development and production of human biological materials, 119-121, 125
- Nonprofit organizations
 - patenting federally funded inventions, 50
 - role in procurement and distribution of human biological materials, 13, 121-124, 125
- Office of Technology Assessment
 - "New Developments in Biotechnology " series, iii
 - survey of Institutional Review Boards, 96
- Oldham, R.K.
 - foundation of Biotherapeutics, Inc., 62
- Organ donations
 - ethical considerations, 130, 131-132, 139, 141, 142, 143
 - law and regulations, 3, 75-76, 87
 - payments for, 75-76, 87, 118
- Ostrach, Michael S.
 - on documentation of consent, 113
- Patent and Trademark Amendment Act
 - patenting and licensing of products of government-sponsored research, 7, 50
- Patent and Trademark Office
 - position on patentability of organisms, 49, 50
- Patent law
 - effect on transfers of human biological materials, 12, 50-51, 52
 - relevance to human biological materials, 7, 16-17, 24n, 49-50, 63, 70-72, 81, 87
- Patients. See *also* Sources of human biological materials
 - rights and interests, 7, 16-19, 21, 26, 51, 63, 71, 78-87, 93-111
- Payments for human biological materials
 - relation to value, 123-124
 - to physicians and researchers, 119
 - to sources, 12-13, 15-16, 55-56, 75-76, 100, 108, 115-121, 125, 141-142
- Pearson v. Dodd**
 - applicability to subcultures from existing cell lines, 81
- Pew Memorial Trust
 - establishment of National Disease Research Interchange, 123
- Pharmaceutical industry
 - acquisition of human biological materials, 52, 55-56
 - effects of 1980 patent law changes, 50-51
 - interest in human tissues and cells, 56-62
 - payments to researchers and physicians, 119
 - research and development, 61
 - testing, 35, 54, 154
- Philosophy
 - moral status of bodies and their parts, 132-134, 137-138, 142, 143
- Physicians
 - acquisition of human biological materials, 52, 73-75
 - consulting relationships with biotechnology and disclosure requirements, 18-19, 93-111
 - fiduciary duty, 82-83, 97, 121
 - pharmaceutical companies, 119
 - relationship with patients, 14, 51, 97-98, 117, 129
- Pituitary hormone preparations
 - transmission of Creutzfeld-Jakob disease, 118
- Pius XI
 - on moral status of bodies and their parts, 141
- Pius XII
 - on compensation for organs and tissues, 141-142
- Policy on human biological materials
 - effect of religion on law and public opinion, 14, 138
 - issues and options for Congress, 15-19
- President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research
 - study of informed consent, 99
- "Product of nature" doctrine
 - patentability of cell lines, 50
- Profits. See Financial gain
- Property law
 - relevance to use of human tissues and cells, 9
- Property rights
 - human biological materials, 24-27, 69-87, 127
- Presser, William
 - on wrongful acts toward cadavers, 72-73
- Protection of Human Subjects (45 CFR Part 46)
 - guidelines
 - adequacy for regulation of use of human tissues and cells in biotechnology, 17-18
- Protestantism
 - moral status of bodies and their parts, 142-143
- Public domain
 - unregistered cell lines, 17
- Ramsey, Paul
 - principle of respect for persons, 131-132
- Recombinant DNA
 - copyrightability, 78
 - gene probe, 43-44
 - increased use of human specimens, 52
 - mechanism, 42-43
 - synonymous with genetic engineering, 41
 - technology, iii, 5-6, 35, 41-45
 - use with monoclonal antibody technology, 38
- Religion
 - impact on use of human biological materials, 13-15, 138-144
- Remedies
 - cases involving human biological materials, 84-86
- Repositories
 - supplying human biological materials to researchers, 52-53

- Res nullius
law of conversion and trespass to chattel, 82-83
- Research
commercial interest, 3, 8, 49-51
consent and disclosure requirements, 93-98, 100-106, 110-111
emotional distress claims, 73-75
ethical considerations, 129-144
fee-for-service, 62
funding, 50, 63, 154
Judaism, 139, 141
patent law, 70-72, 87
purposes, 54
regulation, 10, 11, 17-19, 47, 107-108, 110-111, 149-154
use of human biological materials, 8, 54-55, 62-63
- Research subjects. See *also* Sources of human biological materials
interests, 51
legal dynamics of relationship with researchers, 97-98
not considered inventors, 71
payment, 62
rights, 16-19, 83, 93-111, 147-154
- Researchers
acquisition of human biological materials, 52
consulting relationships with biotechnology and pharmaceutical companies, 119
interests, 8, 52-56
relationship with sources of human tissue, 51, 97-98
responsibilities to subjects, 93-111
rights, 4, 12, 70-72, 83-84, 107, 115, 119, 130
transfers of human biological materials, 52
wrongful acts, 73-75
- Respect for persons
ethics of buying and selling human biological materials, 130-134
justice, 135-136
Protestantism, 142
- Roche Institute of Molecular Biology
development and ownership of KG-1 cell line, 25
- Roman Catholicism
moral status of bodies and their parts, 141-142
- Scholendorff v. Society of New York Hospital***
informed consent and disclosure, 91
- Scientists. See Researchers
- Semen sales
law, 76-77, 87
- Silvestri v. Grant***
patentability decision, 71-72
- Slavin, Ted
marketing blood, 24
- Sources of human biological materials. See *also* Research subjects; Patients
basis of researchers' choices, 54
coercion of, 44, 77, 96-98, 109, 134-135
collection and compensation, 52
emotional distress claims, 73-75
identification, 4
interests, 51
not considered inventors, 71
payment, 12-13, 15-16, 55-56, 62, 75-76, 115-120, 124-125
rights, 4, 9, 16-17, 67, 70-84, 87, 119, 124, 130
- Specification doctrine
law of accession, 84
- Stanford University
ownership dispute over WI-38 cell line, 25
- State law
blood and semen sales, 76, 87
consent and disclosure requirements, 94, 95-96, 98-100, 104, 110-111
conversion and trespass to chattel, 79, 80, 85-86, 87
cultures and micro-organisms as trade secrets, 78
implied warranties in sales of human blood and semen, 77
organ donation, 75
personal rights, 69-70
tax on blood sales, 78, 87
- Storage
human cells, 33, 34ph
- Supply. See Availability
- Supreme Court, US.
Brenner v. Manson patentability decision, 71
Diamond v. Chakrabarty organism patentability decision, 49, 50, 71
effect of actions on sources of human tissue, 51
1980 ruling on patentability of new life forms, 7
- T cell hybridomas
lymphokine production, 40
- T lymphocytes
function and use, 38-40
- Tax law
sale of blood, 78, 87
- Tennessee Supreme Court
tax on blood sales, 78
- Theology
use of human biological materials, 131-132, 138, 139, 142, 143
- Thomasson, Mildrene C.
on research use of human biological materials, 21
- Tissue culture
technology, 5, 31-55
- Tissues, human
applicability of cadaver law, 73
as property, 69-87
difficulty in establishing value, 116
donation, 139, 141
emotional distress claims, 73-75
House Committee on Science and Technology survey of research use, 49-56
industry interest, 56-62
reasons for removal, 51
relative rarity, 55-56
repositories, 52-53
sources, 7-8
sources' interests, 51
trade secrets, 79, 87
- Tort law
relevance to use of human biological materials, 9, 69, 70, 72-73, 87

- Totality
 moral status of bodies and their parts, 141
- Trade secrets law
 source of rights relating to human biological materials, 78-79, 87
- Transfer of human biological materials
 among researchers, 52
 confidentiality agreements, 78-79
 effect of payments to sources on equity, 116, 117
 impact of religious traditions, **143**
 moral and ethical considerations, 15, 129, 143-144
 organ donation law, 75, 87
 ownership rights, 52
- Trespass-to-chattel law
 source of rights relating to human biological materials, 79-83, 87
- Undeveloped human biological materials
 distinct from biological inventions, 24
- Uniform Anatomical Gift Act
 regulation of human organ donation, 3, 75
 uniform Commercial Code
 applicability **to blood and semen sales**, 76-78, 87
- Uniform Trade Secrets Act
 applicability to human tissues and cells, 79
- Universities
 increased patent applications after 1980 patent law changes, 50
 profits from government-funded research, 17
 relations with industry, 7, 50, 54, 61-62, 119
- University of Alabama
 project on availability of tissues for research, 53-54
- University of California, Los Angeles Medical Center
 cell line development, 25-26
- University of California, San Diego
 development and ownership of Hagiwara hybridoma, 26
- University of Minnesota Hospital
 "Liver Tissue Procurement and Distribution System," 53
- Waiver of consent requirements
 Federal regulations, 95
- Waiver of patient's and research subjects' rights
 Federal regulations, 107, 110-111
 fee-for-service research, 62
 removal of ban in Department of Health and Human Services regulations, 18
 University of California, Los Angeles-Moore ownership case, 26
- warranties) **implied**
 blood and semen sales, 76-77
- West, W.H.
 foundation of Biotherapeutics, Inc., 62
- White blood cells. See Lymphocytes
- WI-38 normal human cells
 development and ownership, 25



"The Far Side" cartoon panel is reprinted by permission of Chronical Features, San Francisco